Home
Products

Recombinant Proteins
Bioactive Proteins Cytokines and Growth Factors Immune Checkpoint Proteins Enzyme Other Proteins

Antibodies
Primary antibodies Recombinant Monoclonal Antibodies Secondary antibodies Flow Cytometry (FACS) Antibodies Neutralizing Antibodies Isotype Controls Research Grade Biosimilars InVivo Plus InVivo Antibodies XtenNano®Nanobodies Bispecific Antibodies Antibodies against Small Molecules Tag Antibodies Anti-idiotype Antibodies

Assay Kits
ELISA Kits ADA Assay Kits PK Assay Kits Antibody Pairs
Research Area
Featured Products
Support
Information
- BioSpotlight
- Literature Highlights
About Us
Promotion Center

Vaccination elicits HIV broadly neutralizing antibodies in primates

Nature

The high antigenic diversity of HIV has been a major obstacle to development of a broadly protective vaccine. Here we report testing of an adjuvanted protein germline-targeting vaccine in outbred non-human primates. The vaccine generated bnAb-class memory B cells and sera capable of neutralizing diverse HIV clinical isolates. bnAb lineages were generated in at least 50% of animals, achieving up to 67% neutralization breadth compared with the reference bnAb. Vaccine-induced bnAbs exhibited precise structural mimicry of human bnAb interactions with HIV envelope (Env), matching the germline-targeting predictions. Furthermore, serum bnAb activity developed in 44% of animals and in one instance reached titres expected to confer protection against diverse HIV isolates.

Related products

Catalog No.	Product Name	Description	Target
HB199207	Anti-Human CD154/CD40LG/TNFSF5 Antibody (5C8)		CD154, CD40 ligand, CD40 ligand, membrane form, CD40 ligand, soluble form, CD40-L, CD40L, CD40LG, T-cell antigen Gp39, TNF-related activation protein, TNFSF5, TRAP, Tumor necrosis factor ligand superfamily member 5, sCD40L

Recombinant Proteins

Antibodies

Assay Kits

Vaccination elicits HIV broadly neutralizing antibodies in primates

Quick access

Contact Us